Skip to main content

Schizophrenia & Psychotic Disorders

Two advisory committees appointed by the US Food and Drug Administration (FDA) have voted in favor of ALKS 3831, a combination of olanzapine and the novel molecular entity samidorphan, Alkermes announced.
Patients initiated on long-acting injectables for the treatment of schizophrenia had fewer hospitalizations and emergency department visits, compared with patients treated with oral antipsychotics, according to a poster presented at Psych Congress…
The metabolic profile of lumateperone 42 mg appears favorable, according to a post hoc analysis of a trio of studies involving patients with schizophrenia. Researchers shared their findings at Psych Congress 2020.
A 6-month extension of a published short-term trial showed continued improvement with SEP-363856 in patients with schizophrenia, researchers reported in a poster at Psych Congress 2020.
In patients with recent-onset schizophrenia, the rate of major treatment failure with longer treatment was lower with paliperidone palmitate than with oral antipsychotics, according to a poster presented at Psych Congress 2020. 
In this podcast, Jonathan Meyer, MD, discusses the role of D2 antagonism in schizophrenia treatment, lessons learned about schizophrenia treatment from clozapine, and emerging treatments for…
What does in utero malnutrition have to do with schizophrenia? And why is weight gain, a problematic adverse event, also linked with clinical effectiveness of antipsychotic medications? 
Why do so many antipsychotic medications induce symptoms, signs, and physiologic changes that are already present to a lesser degree in the disease states that they are intended to treat?
Back to Top